Novavax Inc (NVAX) — 8-K Filings

8-K Filings (36)

• 8-K Filing — May 6, 2026
• Novavax Files 8-K on Financials — Nov 6, 2025 Risk: low
  On November 6, 2025, Novavax, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as fi
• Novavax Files 8-K Report — Nov 4, 2025 Risk: low
  On November 3, 2025, Novavax, Inc. filed an 8-K report detailing events that occurred on the same date. The filing indicates updates related to financial statem
• Novavax Files 8-K: Material Agreements and Impairments — Oct 22, 2025 Risk: medium
  On October 17, 2025, Novavax, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also r
• Novavax Files 8-K: Regulation FD, Other Events, Financials — Oct 7, 2025 Risk: low
  On October 1, 2025, Novavax, Inc. filed an 8-K report detailing events including a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits
• Novavax Files 8-K Report — Aug 27, 2025 Risk: low
  On August 27, 2025, Novavax, Inc. filed an 8-K report detailing various events. The filing includes information on financial statements and exhibits, as well as
• Novavax Files 8-K: Material Agreement, Equity Sales — Aug 21, 2025 Risk: medium
  On August 20, 2025, Novavax, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also re
• Novavax Files 8-K on Security Holder Vote Matters — Jun 24, 2025 Risk: low
  On June 20, 2025, Novavax, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing does not disclose specific detai
• 8-K Filing — Jun 11, 2025
• Novavax Announces Board and Executive Changes — May 27, 2025 Risk: medium
  On May 27, 2025, Novavax, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the departure of
• Novavax Files 8-K: Regulation FD Disclosure & Other Events — May 19, 2025 Risk: low
  On May 16, 2025, Novavax, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing does not contain specific financial figures
• Novavax Enters Material Definitive Agreement — May 5, 2025 Risk: medium
  On May 5, 2025, Novavax, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, such as the counte
• Novavax Announces Executive and Director Compensation Changes — Apr 29, 2025 Risk: medium
  On April 25, 2025, Novavax, Inc. filed an 8-K report detailing changes in its executive and director compensation arrangements. The filing also announced the el
• Novavax Files 8-K: Regulation FD Disclosure — Apr 23, 2025 Risk: medium
  On April 23, 2025, Novavax, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, suggesting the company is releasing material non-public i
• Novavax Files 8-K for Regulation FD Disclosure — Apr 2, 2025 Risk: medium
  On April 2, 2025, Novavax, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, indicating a potential release of material non-publ
• Novavax Terminates Material Definitive Agreement — Mar 11, 2025 Risk: medium
  On March 7, 2025, Novavax, Inc. reported the termination of a material definitive agreement. The filing does not specify the counterparty or the nature of the a
• Novavax Files 8-K Report — Mar 4, 2025 Risk: low
  On March 4, 2025, Novavax, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates or disclosure
• Novavax Files 8-K on Financials — Jan 13, 2025 Risk: medium
  On January 13, 2025, Novavax, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and
• Novavax Completes Asset Acquisition/Disposition — Dec 30, 2024 Risk: medium
  On December 30, 2024, Novavax, Inc. filed an 8-K report indicating the completion of an acquisition or disposition of assets. The filing does not specify the na
• Novavax Signs Material Definitive Agreement — Dec 18, 2024 Risk: medium
  On December 12, 2024, Novavax, Inc. entered into a material definitive agreement. The filing does not disclose the specific details of this agreement, such as t
• Novavax Enters Material Definitive Agreement — Dec 4, 2024 Risk: medium
  On December 3, 2024, Novavax, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, such as the c
• Novavax Files 8-K Report — Nov 20, 2024 Risk: low
  On November 19, 2024, Novavax, Inc. filed an 8-K report to disclose information under Regulation FD and to file financial statements and exhibits. The filing do
• Novavax Files 8-K with Financials and Other Events — Nov 12, 2024 Risk: low
  On November 11, 2024, Novavax, Inc. filed an 8-K report detailing a Regulation FD Disclosure and other events. The filing also includes financial statements and
• Novavax Enters and Terminates Material Agreements — Nov 5, 2024 Risk: medium
  On November 1, 2024, Novavax, Inc. entered into a Material Definitive Agreement and also terminated a Material Definitive Agreement. The specific details of the
• Novavax Files 8-K Report — Oct 16, 2024 Risk: low
  On October 16, 2024, Novavax, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial statements and
• Novavax Partners with Sanofi on Flu/COVID-19 Vaccine — Oct 3, 2024 Risk: medium
  On October 2, 2024, Novavax, Inc. announced a new collaboration with Sanofi to develop and commercialize a combination vaccine for influenza and COVID-19. This
• Novavax Appoints New CEO, Dr. John C. Jacobs — Jun 14, 2024 Risk: medium
  On June 13, 2024, Novavax, Inc. announced the appointment of Dr. John C. Jacobs as its new Chief Executive Officer, succeeding Dr. Gregory M. Glenn. Dr. Jacobs,
• Novavax Files 8-K Report — Jun 6, 2024 Risk: low
  On June 6, 2024, Novavax, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing includes financial statements and exhibits,
• Novavax Appoints Dr. John C. Jacobs as New CEO — May 23, 2024 Risk: medium
  On May 20, 2024, Novavax, Inc. announced the appointment of Dr. John C. Jacobs as its new Chief Executive Officer, succeeding Dr. Gregory M. Glenn. Dr. Jacobs,
• Novavax Acquires Takeda's Vaccine Business — May 13, 2024 Risk: medium
  On May 10, 2024, Novavax, Inc. entered into a Material Definitive Agreement related to its acquisition of the global vaccine business of Takeda Pharmaceutical C
• Novavax Files 8-K: Financials and Operations Update — May 10, 2024 Risk: medium
  On May 10, 2024, Novavax, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits, provid
• Novavax Files 8-K Report — Apr 26, 2024 Risk: low
  On April 22, 2024, Novavax, Inc. filed an 8-K report. The filing primarily concerns amendments to its Articles of Incorporation or Bylaws and the submission of
• Novavax Secures $300M Credit Facility — Mar 26, 2024 Risk: medium
  On March 22, 2024, Novavax, Inc. entered into a Material Definitive Agreement, specifically a Credit Agreement with an initial aggregate principal amount of $30
• Novavax Reports Entry and Termination of Material Agreements — Feb 22, 2024 Risk: medium
  Novavax, Inc. filed an 8-K on February 22, 2024, reporting an event on February 16, 2024, concerning both the entry into and termination of a material definitiv
• Novavax Reports Costs Tied to Exit/Disposal Activities — Jan 31, 2024
  Novavax, Inc. filed an 8-K on January 31, 2024, reporting an event that occurred on January 30, 2024, related to "Cost Associated with Exit or Disposal Activiti
• Novavax 8-K: Financial Condition & Operations Update — Jan 8, 2024
  Novavax, Inc. filed an 8-K on January 8, 2024, to disclose information under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX